Search filters
Filters
Clear All

Phase

  • 2
  • 19
  • 2
  • 3
  • 22
  • 48
  • 32
  • 3
  • 45

Found 48 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study of ATRN-119 In Patients With Advanced Solid Tumors (ATRN)

18 years and older
All genders
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
Learn More

UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

99 years and younger
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
Learn More

UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
Learn More

UPCC 32922: A Phase 1 First-in-Human Study of IK-930 an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol, Section 1.1.3. (Study Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints)
Learn More

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Learn More

UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
Learn More

UPCC 18920: A Phase 1 First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors

99 years and younger
All genders
Phase 1
This study tests the effects of an investigational product, CT-0508, and to see how safe CT-0508 is for patients with advanced cancer. One purpose of this study is to see if CT-0508 cells can be made and then safely given back to patients with HER2-positive cancers. A second purpose is …
Learn More

UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)
Learn More

UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
Learn More
1 - 10 of 48